ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results Life Science Investing
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression Life Science Investing
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results Life Science Investing
NRx Pharmaceuticals Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality Life Science Investing
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Life Science Investing
BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study Biotech Investing
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates Life Science Investing
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update Life Science Investing
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates Life Science Investing
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates Life Science Investing
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer
